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Extracellular vesicles with altered 
tetraspanin CD9 and CD151 levels 
confer increased prostate cell 
motility and invasion
Joshua S. Brzozowski  1,2, Danielle R. Bond1,3, Helen Jankowski1,2, Belinda J. Goldie1,4, 
Rachel Burchell1,2, Crystal Naudin2,5, Nathan D. Smith6, Christopher J. Scarlett1,3, Martin R. 
Larsen7, Matthew D. Dun  1,2, Kathryn A. Skelding1,2 & Judith Weidenhofer1,2
To facilitate intercellular communication, cells release nano-sized, extracellular vesicles (EVs) to 
transfer biological cargo to both local and distant sites. EVs are enriched in tetraspanins, two of which 
(CD9 and CD151) have altered expression patterns in many solid tumours, including prostate cancer, as 
they advance toward metastasis. We aimed to determine whether EVs from prostate cells with altered 
CD9 and CD151 expression could influence cellular behaviour and increase the metastatic capabilities 
of non-tumourigenic prostate cells. EVs were isolated by ultrafiltration and characterised for their 
tetraspanin expression and size distribution. iTRAQ was used to identify differences between RWPE1 
and tetraspanin-modified RWPE1 EV proteomes, showing an enrichment in protein degradation 
pathways. Addition of EVs from RWPE1 cells with reduced CD9 or increased CD151 abundance resulted 
in increased invasion of RWPE1 cells, and increased migration in the case of high CD151 abundance. 
We have been able to show that alteration of CD9 and CD151 on prostate cells alters the proteome of 
their resultant EVs, and that these EVs can enhance the migratory and invasive capabilities of a non-
tumourigenic prostate cellular population. This work suggests that cellular tetraspanin levels can alter 
EVs, potentially acting as a driver of metastasis in prostate cancer.
The tetraspanin superfamily is a highly conserved family of proteins with at least 33 members identified in 
humans, including CD9, CD63, CD81 and CD1511. They are involved in the regulation of a number of cellular 
functions, including cellular motility and migration, and as such, have demonstrated involvement in the dissemi-
nation and metastasis of tumours (reviewed by Zöller1). Although tetraspanins alone have not shown any intrinsic 
signalling pathway activations, they serve as molecular organizers of the plasma membrane of cells and facili-
tate the actions of their partner molecules, including integrins, members of the immunoglobulin superfamily, 
and matrix metalloproteinases. Tetraspanins along with their partner molecules can form tetraspanin-enriched 
microdomains or the ‘tetraspanin web’ that act as signalling platforms allowing tetraspanins to influence cellular 
functions. In prostate cancer, the altered expression of the tetraspanins CD9 and CD151 is commonly seen as a 
tumour progresses towards a metastatic phenotype. In these cases, CD9 expression is typically decreased and 
CD151 expression is typically increased, and both have been identified as having prognostic significance in pros-
tate cancer2–5.
The dissemination and metastasis of a tumour is a multifactorial process involving the degradation of con-
nective tissue, cellular migration and invasion into and back out of the circulation and lymph systems, and the 
resumption of proliferation within a premetastatic niche at a distant site of the body6. The formation of the 
premetastatic niche involves modulation of the extracellular matrix of a distant organ to a more favourable 
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environment for a metastasizing tumour cell to adhere and form a secondary tumour mass7. This process requires 
a variety of different molecular drivers, including proteases that degrade matrix components and chemokines that 
can recruit bone marrow progenitor cells to promote angiogenesis8. Whilst it is not fully known why the activity 
and expression of these molecules changes, extracellular vesicles (EVs) have been proposed to be involved.
One of the more highly researched classes of EVs are exosomes – nano-sized membranous vesicles ranging 
from 30–120 nm in diameter. They are formed intraluminally, utilizing endosomal complex required for trans-
port (ESCRT)-dependent or -independent pathways. The tetraspanin CD63 has been reported to coordinate 
both ESCRT-dependent and -independent pathways for exosome formation9, following the identification of the 
secretion of exosomes from cells lacking the ESCRT proteins10. The importance of tetraspanins in the formation 
and function of exosomes was further demonstrated when it was shown that dendritic cells derived from CD9 
knockout mice produced fewer exosomes compared to control mice11, and that Tspan8 expression on exosomes 
was able to contribute to target cell selection12. There are many reported roles for exosomes in the body including 
antigen presentation and immune regulation13–15, the maintenance of homeostasis in neighbouring cells16 and the 
formation of the premetastatic niche17,18.
Typically, when prostate cancers become more aggressive and progress towards a metastatic phenotype, 
they experience alterations in tetraspanin expression, where CD9 levels decrease and CD151 levels increase2,4. 
Additionally CD9 and CD151 have been shown to form heterodimers to a small extent19 and therefore an integral 
component of the study described herein was the expression of these tetraspanins on EVs, and how these EVs can 
impact the function of a non-tumourigenic cellular population. EVs are increasingly being investigated for their 
role in the communication between cells, both locally and throughout the body. Whilst it is known that tumour 
cells displaying an altered CD9 and CD151 expression pattern have a higher invasive capacity than other cells, 
little is known as to what alteration of these tetraspanins does to the function and proteomic composition of EVs 
and what impact the changes will have on key metastatic functions. It is also unknown what impact these EVs will 
have on surrounding cells, and whether they can alter the phenotype of a non-tumourigenic cellular population to 
adopt a more aggressive and invasive one. In this study, we explored the function of CD9 and CD151 on prostate 
EVs following treatment of non-tumourigenic RWPE1 prostate cells with EVs from RWPE1 cells with altered 
CD9 and CD151 expression or EVs from a tumourigenic prostate cell line. We further went on to quantitatively 
identify differences in the proteome of these EVs to determine whether the recruitment and abundance of pro-
teins could explain the effects observed.
Results and Discussion
EVs reflect the CD9 and CD151 patterns of their cells of origin. Considering the relationship 
between decreased CD9 and increased CD151 expression in prostate cancer cells with the progression towards 
metastasis, and the potential for EVs to drive the formation of the premetastatic niche, we were interested to see 
if the abundance of CD9 and CD151 on EVs was directly related to their cellular expression. Thus, we modified 
the expression of CD9 and CD151 in RWPE1 cells and isolated EVs from cell culture media by ultrafiltration. 
Characterising the EVs with nanoparticle tracking analysis (NTA) showed that altering the cellular tetraspanin 
profile did not alter the size of EVs, which were all within the classically defined 30–120 nm range for exosomes. 
As it has previously been shown that tumour cells secrete larger numbers of EVs compared to non-tumourigenic 
cells20,21, we were interested to see if altering the tetraspanin expression in RWPE1 cells altered the number of EVs 
produced by these cells. There were no differences in concentrations of EVs released from CD9 low or CD151 
high RWPE1 cells compared to unmodified RWPE1 cells, however, the concentration of EVs was significantly 
decreased in CD151 high EVs compared to CD9 low (p = 0.0159) and WPE1-NB26 (p = 0.0148) EVs (Fig. 1). 
Further, all EVs were positive for CD9 and CD63 expression, common markers of EV populations (Fig. 2B), 
although differences in abundance of these markers were detected.
CD9 and CD151 abundance in cells and EVs was determined by western blot, with densitometry highlighting a 
significant decrease in cellular CD9 content for CD9 low (−79.14%, p = 0.0021), CD151 high (−82.10%, p = 0.0015) 
and WPE1-NB26 (−65.61%, p = 0.0123) cells compared to RWPE1 cells, with no significant differences in cells 
transfected with the Scrambled (p = 0.9162) and Empty Vector controls (p = 0.1937) (Fig. 2A,C). For CD151 expres-
sion of cells, the CD151 high cell line displayed a significant increase in CD151 protein expression compared to 
RWPE1 cells (2,879.85%, p < 0.0001) (Fig. 2C), however the extreme increase in CD151 expression in the CD151 
high cell line was masking other significant differences between the other cell lines used when compared using 
Bonferroni’s multiple comparisons test. To overcome this, the CD151 high cell line was excluded from a second 
multiple comparisons test, and by doing so, the WPE1-NB26 cell line also displayed a significant increase in CD151 
expression compared to RWPE1 cells (261.32%, p < 0.0001). CD9 low, Scrambled and Empty Vector cells all showed 
no significant difference in CD151 protein expression compared to RWPE1 cells (p > 0.9999).
In regards to EV tetraspanin expression, only the EVs derived from CD9 low cells displayed significantly 
reduced CD9 expression compared to EVs derived from RWPE1 cells (−84.27%, p = 0.0351) (Fig. 2B,C). Scrambled 
(p > 0.9999), CD151 high (p = 0.1644), Empty Vector (p = 0.7210) and WPE1-NB26 (p = 0.4393) EVs had no sig-
nificant differences in CD9 expression compared to RWPE1 EVs. For CD151 expression, EVs derived from CD151 
high (1,219.24%, p < 0.0001) and the WPE1-NB26 (223.41%, p = 0.0079) cells displayed significantly increased CD151 
expression compared to EVs derived from RWPE1 cells. EVs from CD9 low (p > 0.9999), Scrambled (p > 0.9999) and 
Empty Vector (p = 0.8099) cells had no significant differences in CD151 expression compared to RWPE1 EVs. Further, 
analysing the relative abundance of CD151 and CD9 in the cells compared to the EVs showed no difference in either 
tetraspanin, except for CD151 in CD151 high cells and EVs (p < 0.0001), as determined by two-way ANOVA with 
Bonferroni’s multiple comparisons after normalising to RWPE1 abundance (data not shown). These results suggest 
that the abundance of CD9 and CD151 on EVs is, to a large extent, driven by the cellular abundance of the parent cell. 
This has potential implications for the assessment of EVs using the presence of CD9 as a marker of EV sub-populations.
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To determine if the findings of altered tetraspanin abundance were restricted to CD151 and CD9 an additional 
tetraspanin, CD82, was also assessed in cell and EV lysates (Fig. 2A,B). CD82 functions as a metastasis suppressor 
by interfering with the activation of integrin β1 (ITGB1), causing a decrease in cellular motility and invasion22 
and by stabilising E-cadherin/β-catenin complexes, maintaining strong cell-cell adhesion to inhibit the dissemi-
nation of cancer cells23. When compared to RWPE1 cells, CD9 low (p > 0.9999), Scrambled (p > 0.9999), CD151 
high (p = 0.6410) and Empty Vector (p > 0.9999) cells did not significantly differ in CD82 expression, however, 
WPE1-NB26 cells had negligible CD82 expression (p < 0.0001) (Fig. 2D), indicative of the invasive and meta-
static nature of this cell line. In EVs, CD82 abundance was not significantly different in CD9 low (p = 0.7073), 
Scrambled (p > 0.9999), CD151 high (p > 0.9999) or Empty Vector (p > 0.9999) samples compared to RWPE1 
EVs (Fig. 2D). Although WPE1-NB26 EVs had negligible CD82 expression, as was seen in the cells, the differ-
ence failed to reach significance when compared to RWPE1 EVs (p = 0.3343), possibly due to the larger var-
iation in abundance of CD82 in the EVs tested. To assess whether there were differences in the abundance of 
CD82 between cells and EVs, cellular and EV abundance was normalised to RWPE1 abundance and compared 
using two-way ANOVA with Bonferroni’s multiple comparisons. There were no significant differences observed 
between the cellular and EV abundance of CD82 (data not shown). Although not directly assessed here, the find-
ing that these three tetraspanins (CD9, CD151 & CD82) show a correlation between cellular and EV expression, 
suggests that the other commonly used EV markers, CD63 and CD8124, may also show this pattern. Therefore, 
if these tetraspanins have low abundance in a cellular population, the expression may be undetectable in EVs, 
confounding the identification of EV subtypes.
Tetraspanins are known to be important in cell signalling, particularly through the organisation of the tet-
raspanin web on the cell surface. In order to determine whether the cell surface tetraspanin expression is respon-
sible for the expression seen in EVs, we assessed cell surface-specific expression of CD9 and CD151 using flow 
cytometry. This showed the same overall pattern of CD9 expression as for the total expression with a signifi-
cant decrease in CD9 low (−42.36%, p = 0.0016) and CD151 high (−39.54%, p = 0.0036) cell lines compared 
Figure 1. Average size distribution curve of EVs determined by NTA. Three 60 s videos were recorded for each 
sample, and NTA analysis settings kept constant between samples. The average concentration of vesicles was 
plotted against their size with error bars representing the standard deviation in concentration in 10 nm size 
increments. The mean and mode sizes and the average concentration are given ± standard deviation.
www.nature.com/scientificreports/
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to the RWPE1 cell line, with no significant differences observed for the Scrambled (p = 0.0976), Empty Vector 
(p = 0.4636) and WPE1-NB26 (p = 0.3794) cell lines (Fig. 2E). In concordance to total CD151 expression, both 
the CD151 high (342.80%, p < 0.0001) and WPE1-NB26 (53.92%, p = 0.0030) cell lines displayed significantly 
higher surface expression of CD151 when compared to the RWPE1 cell line, with no significant differences 
observed for the CD9 low (p > 0.9999), Scrambled (p > 0.9999) and Empty Vector (p = 0.6250) cell lines (Fig. 2E). 
It has been previously shown that the binding of different monoclonal antibodies (mAb) to CD151, including 
mAb 11B1 used in this study, can be affected by partner molecule binding to CD151 masking the antibody bind-
ing epitope25. The consequence of such interactions could lead to an underrepresentation of the total CD151 
content in flow cytometry experiments, where these interactions are not disrupted by detergents, as occurs during 
western blotting. Considering this limitation, the data here show that cellular abundance of CD9 and CD151 is 
directly related to abundance in EVs. Further analysis of tetraspanin abundance is required, using antibodies that 
recognise specific pools of bound and unbound tetraspanins, to determine if cell surface abundance is correlated 
with EV abundance in the same way. There have been speculations that members of the tetraspanin family are 
important for the formation and cargo recruitment of EVs26, however it is relatively unknown whether alterations 
in the tetraspanin expression of EVs will affect their function and composition.
Figure 2. Cell and EV Tetraspanin Expression. (A) Cells were assessed for their total CD9, CD151 and 
CD82 content via western blot, with GAPDH used as a loading control. (B) EVs were assessed for their total 
CD9, CD151 and CD82 content via western blot, using Ponceau-S stained bands as a loading control. EVs 
were further assessed for the expression of CD63, a common EV marker. (C) Differences in CD9 and CD151 
expression compared to RWPE1 cells and EVs were determined using one-way ANOVA with Bonferroni’s 
multiple comparisons test. CD9 low, CD151 high and WPE1-NB26 cells all showed a significant decrease in 
CD9 expression compared to RWPE1 cells, however only CD9 low EVs had a significant decrease in expression 
compared to RWPE1 EVs. Both CD151 high and WPE1-NB26 cells and EVs showed significant increases in 
CD151 expression compared to RWPE1 cells and EVs. (D) Differences in CD82 expression in cell and EV 
lysates were determined as above. WPE1-NB26 cells and EVs were negative for CD82 expression, whereas 
alterations in CD9 and CD151 expression did not significantly affect CD82 abundance in either cells or EVs. 
(E) Cell surface expression of CD9 and CD151 was determined using flow cytometry, and one-way ANOVA 
with Bonferroni’s multiple comparisons test was used to determine significance. CD9 low and CD151 high cells 
showed significant decreases in CD9 surface expression to RWPE1 cells. CD151 high and WPE1-NB26 cells 
showed significant increases in CD151 surface expression to RWPE1 cells. Data shown are representative of at 
least three independent experiments. *P < 0.05; **P < 0.01; ****P < 0.0001. Error bars are SEM. Western blot 
images are cropped, with full-length blots presented in Supplementary Fig. S7.
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Alterations in CD9 and CD151 abundance on EVs affects their proteome. Since the abundance 
of CD9 and CD151 on EVs varied with cellular abundance, and tetraspanins have been proposed to influence 
EV cargo recruitment, we examined the proteome of the EVs using quantitative proteomics with isobaric tags 
(iTRAQ™ labels). Peptide analysis, after filtering for proteins of human origin only, detected 627 proteins that 
had at least one isobaric tagged peptide in common with the RWPE1 EV sample (Supplementary Fig. S1), con-
sistent with numbers identified in other studies27. To determine whether the calculated protein abundance in each 
sample was reliable, the abundance of several traditionally used loading control proteins, including beta actin 
(ACTB), alpha tubulin (TBB5) and beta tubulin (TBA1B), were assessed and relatively equal expression across all 
samples ± 0.006 was found (Table 1). To further validate the iTRAQ peptide analysis, several proteins displaying 
differential expression across all samples were selected for western blot analysis (Fig. 3C). EVs from the RWPE1, 
CD9 low, CD151 high and WPE1-NB26 cell lines were probed for the 78 kDa glucose regulated protein (HSPA5), 
filamin-A (FLNA), transforming growth factor-beta induced protein ig-h3 (TGFBI) and testican-2 (SPOCK2), 
with total actin being used as a loading control. iTRAQ and quantitated western blot data showed similar patterns 
of expression, further confirming the validity of the quantitated iTRAQ values (Table 2).
Identification of interaction networks for all detected protein IDs using FunRich revealed distinct clus-
ters around 14-3-3 protein gamma (YWHAG) and nucleoside diphosphate kinase B (NME2) (Supplementary 
Fig. S2). YWHAG is thought to contribute to cancer progression and increase metastatic spread by promoting 
cancer cell invasion28. Expression ratios of YWHAG in CD9 low and CD151 high EVs indicated a selective sort-
ing when compared to RWPE1 EVs (RWPE1:CD9 low = 1.796; RWPE1:CD151 high = 1.336), however this was 
not observed for WPE1-NB26 EVs (RWPE1:WPE1-NB26 = 0.800). This selective incorporation of pro-metastatic 
messages with cancer relevant modification of CD9 and CD151 abundance suggests that this could be involved in 
the promotion of early stage metastasis through the uptake of these EVs into recipient cells.
Similarly, iTRAQ expression ratios showed a decreased expression of NME2, a transcription regulator of Myc 
with metastasis suppressor functions29, across CD9 low, CD151 high and WPE1-NB26 EV populations compared 
to RWPE1 (RWPE1:CD9 low = 0.358; RWPE1:CD151 high = 0.620; and RWPE1:WPE1-NB26 = 0.577). This sug-
gests that the expression of CD9 may be a contributing factor for NME2 incorporation into EVs, which could 
have similar effects on the progression of cancer. Further, the identification of a number of proteins involved in 
the epithelial-mesenchymal transition (EMT) displayed an increase in abundance in CD9 low, CD151 high and 
WPE1-NB26 EVs compared to RWPE1 EVs, including vimentin30 (RWPE1:CD9 low = 2.818; RWPE1:CD151 
high = 2.265; and RWPE1:WPE1-NB26 = 1.907), moesin31 (RWPE1:CD9 low = 1.811; RWPE1:CD151 
high = 2.022; and RWPE1:WPE1-NB26 = 1.345), and annexin A232 (RWPE1:CD9 low = 1.204; RWPE1:CD151 
high = 1.431; and RWPE1:WPE1-NB26 = 1.362). Taken together, these protein clusters and EMT proteins rep-
resent an enrichment for pro-tumorigenesis pathways through the negative regulation of apoptosis, Myc-related 
metastatic functions, and the possible promotion of EMT by EVs.
To identify proteins with large differences in abundance, the list was filtered for proteins with a ≥ 2-fold 
increase or decrease when compared to RWPE1 EVs. Interestingly there were far more proteins identified with 
increased rather than decreased abundances in any of the comparisons when compared to RWPE1. The greatest 
number of differences were observed for the CD9 low EVs, with 91 proteins increased and 18 decreased when 
compared to RWPE1. In CD151 high EVs, 77 proteins were increased and 6 decreased, and in WPE1-NB26 
EVs, 35 proteins were increased and 8 decreased when compared to RWPE1 (Supplementary Tables S3 and S4). 
Further, visualisation of these proteins with differing abundance using Venn diagrams showed that CD9 low 
EVs had 28 unique proteins (21 increased and 7 decreased), CD151 high EVs had 11 unique increased and 
2 unique decreased proteins, and WPE1-NB26 EVs had 8 unique increased and 4 unique decreased proteins. 
There were 16 increased proteins common between all three comparisons, with CD9 low and CD151 high EVs 
sharing a further 42 increased proteins, CD9 low and WPE1-NB26 EVs sharing 1 increased protein, and CD151 
high and WPE1-NB26 EVs sharing 2 increased proteins in common (Fig. 3A). There was only 1 common pro-
tein decreased in all samples, fumarylacetoacetate hydrolase domain-containing protein 2B (FAHD2B). Due to 
sequence homology, FAHD2B is proposed to have hydrolase and metal binding activity, however, to our knowl-
edge, no further characterisation has been performed on this protein. Further, CD9 low EVs share 1 protein in 
common each with CD151 high and WPE1-NB26 EVs, and CD151 high and WPE1-NB26 EVs share a further 2 
decreased proteins (Fig. 3B).
FunRich analysis was utilized to determine enriched pathways from the iTRAQ datasets that could identify 
potential functions that EVs may transfer to their target cells via their protein content. Protein IDs (UniProt 
Accession) were imported into FunRich where they are converted into gene names for subsequent analysis. For 
all detected protein IDs across all samples, the biological pathways that were most highly enriched were those 
involved with nucleic acid destabilisation and protein degradation (Fig. 3D). These biological processes were 
further analysed for enrichment in the CD9 low, CD151 high and WPE1-NB26 lists with a ≥ 2-fold increase 
in expression compared to RWPE1. For CD9 low EVs, beta2 and beta3 integrin interaction pathways, as well 
as metabolic pathways were the most prevalent (Fig. 3E). Beta2 and beta3 integrin interaction pathways were 
Loading Control RWPE1 CD9 low CD151 high WPE1-NB26
Beta Actin (ACTB) 1.000 1.055 0.858 0.915
Beta Tubulin (TBB5) 1.000 0.912 0.992 1.030
Alpha Tubulin (TBA1B) 1.000 1.026 1.132 1.043
Average 1.000 0.998 0.994 0.996
Table 1. Traditional loading control proteins identified using iTRAQ analysis compared to RWPE1 expression.
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enriched in CD151 high EVs, and an overall enrichment for protein degradation pathways was identified in 
these EVs (Fig. 3F). Integrin interaction and complement activation pathways were the most enriched pathways 
in WPE1-NB26 EVs (Fig. 3G). Due to the interactions that tetraspanins have with integrins, the enrichment for 
integrin interaction pathways was not unexpected.
Figure 3. FunRich analysis of iTRAQ data. (A) Proteins with a ≥ 2-fold increase in expression and (B) a ≥ 2-fold 
decrease in expression when compared to RWPE1 EVs. Venn diagrams were created using the Public Research 
Centre for Health’s Venn diagram generator tool (http://www.bioinformatics.lu/venn.php). (C) Western blot 
analysis of Actin, Filamin-A, TGFBI, HSPA5 and SPOCK2 confirmed iTRAQ quantitated values. (C) Enriched 
biological pathways for all detected EV proteins. Degradation pathways were the predominant feature in the 
total dataset. (D) Enriched biological pathways for CD9 low EV proteins with a ≥ 2-fold increase in expression to 
RWPE1 EVs. (E) Enriched biological pathways for CD151 high EV proteins with a ≥ 2-fold increase in expression 
to RWPE1 EVs. (F) Enriched biological pathways for WPE1-NB26 EV proteins with a ≥ 2-fold increase in 
expression to RWPE1 EVs. Graphs were created using FunRich v2.1.2. which converts protein IDs to gene names. 
Western blot images are cropped, with full-length blots presented in Supplementary Fig. S8.
www.nature.com/scientificreports/
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EVs display protease activity. EV involvement in the metastatic process involves crosstalk between cancer 
cell EVs and surrounding cells of the tumour mass. A crucial step in this process involves cellular migration and 
invasion through the extracellular matrix. Through iTRAQ and subsequent western blot (Fig. 3C), transforming 
growth factor beta-induced protein (TGFBI) was found to have a significantly increased expression in CD9 low 
and CD151 high EV populations. It has previously been reported that TGFBI is an integrin binding partner, capa-
ble of modulating the attachment of cells to fibronectin and collagen components of the extracellular matrix33. 
An increased expression of TGFBI in melanoma cells impaired cellular adhesion to fibronectin, collagen I and 
laminin, conferring strong anti-adhesive function to metastasizing cells34. Another function of cancer cell EVs 
is in the formation of the premetastatic niche; a distant site within the body that has become transformed into a 
more favourable environment for metastasizing tumour cells to settle and grow. This process involves the deg-
radation of extracellular matrix components and the recruitment of various growth factors to promote cellular 
proliferation and neovascularization7. We observed a selective enrichment for the beta subunits 4, 5, 6 and 7 
of the proteasome complex (PSMB4, PSMB5, PSMB6 and PSMB7 respectively) in CD9 low, CD151 high and 
WPE1-NB26 samples compared to RWPE1 EVs. There was also an enrichment for the proteasome activator 
complex subunit 2 (PSME2) in all samples, lending further evidence to the enrichment of protein degradation 
pathways identified by FunRich analysis (Table 3). This increase in abundance of proteins in proteasome degrada-
tion pathways in modified and tumourigenic EVs points towards possible involvement in the metastatic process.
Matrix metalloproteinases (MMPs) are a large family of zinc-dependent endopeptidases with specificity to 
particular ECM substrates35,36. Both MMP2 (gelatinase A) and MMP9 (gelatinase B) are implicated in the pro-
gression and metastasis of many tumours via degradation of the ECM and resultant release of ECM-bound bio-
active molecules that assist in angiogenesis and cellular migration36,37. To assess whether EVs contained active 
MMPs which may aid in the degradation of ECM components, gelatin and casein zymography were used. Gelatin 
zymography showed that all EVs possessed both pro- and active MMP9 activity, with Scrambled and CD151 
high EVs displaying the highest activity, particularly for pro-MMP9. A lesser amount of active MMP2 was also 
detected in RWPE1 and CD151 high EV samples (Fig. 4A). Although a gelatinase, MMP9 can be detected using 
casein zymography if highly abundant35. We were able to further show increased MMP9 activity in CD151 high 
EVs using casein zymography (Supplementary Fig. S5). Taken together, the enrichment of various proteasome 
complex subunits and the expression of active MMPs, particularly in CD151 high EVs, lends evidence to support 
that alteration of tetraspanins in prostate cancer cells may give rise to EVs with enhanced matrix degradation 
properties.
Altered CD9 and CD151 abundance on EVs affects cellular migration and invasion. EVs are able 
to affect target cell function via a number of mechanisms, including internalisation into the target cell via endo-
cytosis, direct fusion with the plasma membrane to release their cargo into the cytoplasm, or by simply binding 
to cell surface receptors to activate internal signalling pathways38. CD151 has reported interactions with various 
integrins, including α3 and α6, which are important for CD151-related roles in many cellular processes includ-
ing, in prostate cancer, migration and invasion39. Further, proteases, particularly MMP2 and MMP9, displayed 
enhanced activity in CD151 high EVs, compared to RWPE1 EVs. MMPs are known to interact with integrins and 
have been shown to enhance tumour cell migration and invasion through the ECM40,41. As integrin interactions 
and proteasome pathways were consistently identified using iTRAQ, we investigated whether our isolated EVs 
could enhance the migratory and invasive capacity of RWPE1 cells when used as a treatment.
Investigating the effects of EVs on their target cells migratory capacity using a wound-healing assay showed 
differential effects, dependent on the tetraspanin level. Treating RWPE1 cells with CD151 high and WPE1-NB26 
Protein
RWPE1* CD9 low CD151 high WPE1-NB26
iTRAQ WB iTRAQ WB iTRAQ WB iTRAQ WB
Filamin-A (FLNA) 1.000 1.000 1.662 2.092 1.684 2.916 1.392 0.724
Transforming growth factor-beta-induced 
protein ig-h3 (TGFBI) 1.000 1.000 2.432 1.471 2.216 1.331 0.737 0.635
78 kDa glucose-regulated protein (HSPA5) 1.000 1.000 1.019 1.052 1.027 1.021 1.015 1.180
Testican-2 (SPOCK2) 1.000 1.000 1.209 1.066 0.913 0.966 2.564 1.455
Table 2. Comparison of iTRAQ and western blot quantitated values. WB = western blot. *All values were 
normalised to RWPE1.
Protein RWPE1 CD9 low CD151 high WPE1-NB26
Proteasome activator complex subunit 2 (PSME2) 1.000 1.505 2.527 1.525
Proteasome subunit beta type-4 (PSMB4) 1.000 1.166 1.770 1.145
Proteasome subunit beta type-5 (PSMB5) 1.000 5.107 3.069 1.368
Proteasome subunit beta type-6 (PSMB6) 1.000 8.963 2.136 1.433
Proteasome subunit beta type-7 (PSMB7) 1.000 4.837 2.768 1.435
Table 3. Abundance changes of proteins involved in proteasome degradation pathways.
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EVs was able to significantly increase RWPE1 cell migration at 24 h post-EV addition when compared to RWPE1 
EV-treated cells (74.88%, p = 0.0163 and 49.56%, p = 0.0331 respectively) (Fig. 4B,C). No significant differences 
in migration were observed by the addition of CD9 low EVs on RWPE1 cells (p = 0.9262) (Fig. 4B). To control 
for any effects of the EVs on cellular proliferation influencing the outcome of these assays, a proliferation assay 
was performed across the range of time points used for migration and invasion assays, up to 48 h. There were no 
significant differences in proliferation observed with any EV treatment at any time point assessed (Fig. 4D). The 
WPE1-NB26 cell line displays an endogenous increase in CD151 and decrease in CD9, whereas the CD151 high 
cell line displays an artificial increase in CD151 and decrease in CD9, with EVs from both cell lines able to provide 
a gain of migratory function to RWPE1 cells. However, the CD9 low cell line displays an artificial decrease in CD9 
whilst retaining normal levels of CD151, with EVs from this cell line being unable to elicit a gain in migratory 
function to RWPE1 cells, suggesting that this gain of function is possibly due to the influence of CD151. This may 
be related to whether the CD151 is bound to integrin partners or whether it remains unbound in the membrane, 
as has been shown by Palmer et al. (2013), where unbound CD151 negatively influenced cellular motility when 
Figure 4. Migration and invasion of EV treated RWPE1 cells. (A) Gelatin zymography of EVs detected MMP2 
and the pro- and active form of MMP9, with an increase in pro-MMP9 observed in Scrambled and CD151 high 
EVs. (B) Both CD151 high and WPE1-NB26 EV treated RWPE1 cells displayed enhanced wound closure using 
a Kruskal-Wallis test. (C) A wound healing assay was performed to determine the migratory capacity of RWPE1 
cells treated with EVs. Red lines indicate the edge of the wound used for calculations. (D) A proliferation assay 
was performed to ensure that effects seen were not due to proliferation. No differences were seen in proliferation 
in EV treated RWPE1 cells. (E) Invasion assay of RWPE1 cells through a BME coating that was pretreated 
with 10 µg EVs for 24 h. No significant differences were observed compared to untreated. (F) Invasion assay 
of RWPE1 cells through a BME coating with co-addition of cells and EVs. CD9 low and CD151 high EVs 
significantly enhanced RWPE1 cell invasion when compared to untreated cells. Significance was determined 
using a Kruskal-Wallis test. All data are representative of three independent experiments. *P < 0.05; **P < 0.01; 
***P < 0.001. Error bars are shown as SEM.
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clustered on the cell surface due to increased cell-cell adhesion42. However, when unbound CD151 is not clus-
tered, it was shown to enhance cellular motility42. Whether the CD151 on EVs is bound or unbound to integrins 
was not determined in this case, however, with the incredibly high levels of CD151 present in the CD151 high 
EVs, it would seem unlikely that it was all bound to integrins. Further, utilising super-resolution microscopy, 
it has been reported that the average size for tetraspanin clusters in the cell membrane is between 35–150 nm 
diameter43,44, making it unlikely that tetraspanins form clusters on EVs. The increase in cellular motility con-
ferred by these EVs also suggests that any unbound CD151 does not become clustered in the membrane of tar-
get cells. To investigate this further, we assessed the CD151 abundance of RWPE1 cells following EV treatment 
(Supplementary Fig. S6), where we observed no significant differences in CD151 content, suggesting that CD151 
may in fact be facilitating the interactions of partner molecules with receptors on the cell membrane to elicit their 
function38.
The ability for EVs to affect cellular invasion through the basement membrane is another key step in the met-
astatic cascade that integrins have been implicated in45, therefore we wanted to determine what impact treating 
RWPE1 cells with EVs arising from cells with differential CD9 and CD151 expression had on their invasive capac-
ity. An invasion assay was performed using EV-treated RWPE1 cells on a basement membrane extract (BME) 
coated well of a Boyden-chamber. Pretreatment of BME with EVs (Fig. 4E) prior to cell addition did not show any 
significant difference in invasion compared to pretreating with PBS (untreated). Co-addition of EVs with cells 
(Fig. 4F) showed significant increases in invasion for both CD9 low EV (99.40%, p = 0.0002) and CD151 high 
EV (87.44%, p = 0.0054) treated RWPE1 cells when compared to untreated RWPE1 cells. Taken together, these 
results indicate that a combination of low CD9 and high CD151 expression, as seen in the CD151 high EVs, can 
influence migration and invasion of non-tumourigenic prostate cells. Low CD9 EV expression alone was only able 
to influence the invasion of a non-tumourigenic cellular population and not migration. As tetraspanins have been 
proposed to influence the uptake of cargo into EVs26, these functional differences between CD9 low and CD151 
high EVs may be attributed to a selective recruitment of cargo molecules that may act on EV target cells to affect 
invasion and migration. Whether the functional effects seen here are due to cellular uptake of EVs and the subse-
quent functional effects of their cargo or EVs binding to cell surface proteins and affecting membrane signalling 
platform organisation requires further investigation.
Although tetraspanins themselves are commonly used as markers of EV populations, including CD63, CD9 
and CD8124, it remains largely unexplored what alterations in tetraspanin expression on EVs has on their func-
tion and composition. An interesting observation in this study was that decreasing CD9 expression in EVs 
resulted in a larger number of significantly increased and decreased changes in the proteome compared to CD151 
high and the tumourigenic WPE1-NB26 EVs, however this larger number of differences did not translate to an 
increased functional gain for RWPE1 cells when they were incubated with CD9 low EVs in the assays assessed. 
The tetraspanin family are thought to be important in the formation and cargo recruitment of EVs26, and the 
data presented here give evidence to support this notion, as we observed subtle but distinct differences in the 
proteome and functional effects of EVs with altered tetraspanin expression. However, as the number of differ-
ences in the proteome of EVs did not necessarily indicate the number of functional differences conferred by those 
EVs, perhaps the nucleic acid or lipid cargo, alone or in combination with the EV proteome may be key to driv-
ing the functional effects seen here, and an assessment of differences in EV cargo may elucidate the underlying 
molecular mechanisms involved. We have also demonstrated that CD9 and CD151 modified, and tumourigenic 
(WPE1-NB26) EVs can transfer metastasis-related function to a non-tumourigenic cellular population. This may 
have implications for tumour-derived EVs in the spread of metastatic potential to other prostate cancer cells 
within the primary tumour mass, priming the metastatic potential of these cells.
Methods
Antibodies. Mouse-anti-CD9 [1AA2], mouse-anti-CD151 [11B1c.4] and isotype controls mouse-anti-
IgG1 [IB5] and mouse-anti-IgG2A [ID4.5] were a gift from C. Prof Leonie Ashman (University of Newcastle, 
NSW, Australia). Commercial antibodies were purchased from the following: Rabbit-anti-GAPDH (BioVision 
#3777R-100; Sapphire Biosciences, Redfern, NSW, Australia), mouse-anti-CD63 (BioVision #A1502-50), 
mouse-anti-CD82 [TS82b] (Abcam #ab59509; Abcam Australia, Melbourne, VIC, Australia), rabbit polyclonal 
HSPA5 (GeneTex #GTX127934; Sapphire Biosciences), FLNA (GeneTex #GTX109931), SPOCK2 (GeneTex 
#GTX121068) and TGFBI (GeneTex #GTX100744). Goat anti-mouse and goat anti-rabbit HRP-conjugated sec-
ondary antibodies were from Bio-Rad (Gladesville, NSW, Australia). FITC-conjugated goat anti-mouse second-
ary antibody was from Southern Bio-tech (In Vitro Technologies, Noble Park, VIC, Australia).
Cell Lines and Cell Culture. The RWPE1 (CRL-11609) and WPE1-NB26 (CRL-2852) cell lines were pur-
chased from American Type Culture Collection (Cryosite, South Grandville, NSW, Australia), with authentica-
tion provided with purchase, and grown in complete Keratinocyte-Serum Free Media (K-SFM) (Gibco, Thermo 
Fisher Scientific, Mulgrave, VIC, Australia) at 37 °C/5% CO2. RWPE1 cells were transfected to display either low 
CD9 or high CD151 expression as detailed below.
Generation of CD151 overexpressing and CD9 knockdown RWPE1 cell lines. For overexpres-
sion of CD151, 2.5 µg of pcDNA3.1/Zeo vector (Invitrogen, Thermo Fisher Scientific) containing the full length 
human CD151 sequence39 was transfected into RWPE1 cells with Lipofectamine LTX (Invitrogen). Cells were 
selected with 500 µg/mL Zeocin (Gibco) to facilitate the production of a stable CD151 overexpressing cell line, 
herein referred to as CD151 high. An empty pcDNA3.1/Zeo vector control line was also generated in this manner, 
herein referred to as Empty Vector.
Stable knockdown of CD9 in RWPE1 cells was conducted as described above using the pRS CD9 shRNA 
vector (Origene Cat# TR314060; Australian Biosearch, Karrinyup, WA, Australia) and selection with 1.5 µg/mL 
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Puromycin (Sigma Aldrich, Castle Hill, NSW, Australia) to achieve stable knockdown of CD9, herein referred to 
as CD9 low. The supplied scrambled shRNA vector (Origene) was also used to generate a control cell line, herein 
referred to as Scrambled.
Extracellular Vesicle Isolation. EVs were isolated from the media of cells following a 72 h incubation using a 
modified ultrafiltration procedure as previously described46. Briefly, 100 mL of spent media per collection was sequen-
tially passed through 0.22 µm PES and 0.1 µm PVDF syringe filters (Merck Millipore, Kilsyth, VIC, Australia). Clarified 
media was then placed in a 100 kDa centrifugal filter unit (Merck Millipore) and centrifuged at 4,000 × g, 4 °C until 
sample had passed through. The flowthrough was discarded and the retentate washed with 0.1 µm filtered sterile PBS 
twice to yield a retentate of concentrated EVs in PBS. Retentates were collected and stored at −30 °C until required.
Nanoparticle Tracking Analysis. Nanoparticle tracking analysis (NTA) was used to determine particle 
size distribution and concentration of EV samples from RWPE1, CD9 low, CD151 high and WPE1-NB26 cell 
lines. Concentrated EV suspensions were diluted 1:1000 in PBS before introduction into the sample chamber of 
a Nanosight NS300 NTA system (Malvern, ATA Scientific, Taren Point, NSW, Australia) using a syringe pump 
(Harvard Apparatus, ATA Scientific) on a speed setting of 50. The NS300 was adjusted so that particles were in the 
focal plane and a scientific CMOS camera captured 3 × 60 s videos per sample. Post-acquisition analysis settings 
were kept constant between samples. Particle size distribution and concentration were determined using NTA 
v2.3 software (Malvern).
Flow Cytometry. Cell surface CD9 and CD151 protein levels of cell lines were determined using a modified 
flow cytometry procedure as previously described47. Briefly, cells were washed and resuspended in NRS/PBA 
(10% normal rabbit serum (Invitrogen), 0.1% BSA, 0.1% sodium azide in PBS) containing either CD9, CD151 
or combined IgG1/IgG2A primary antibodies at 6 µg/mL. Cells were washed in PBA and resuspended in NRS/
PBA containing FITC-conjugated secondary antibody. Cells were washed and fixed prior to analysis using a BD 
FACScalibur flow cytometer using Cellquest Pro® software (both BD Biosciences, North Ryde, NSW, Australia). 
Expression of CD9 and CD151 was analysed using Weasel software (WEHI, Melbourne, VIC, Australia) and 
normalized to their respective isotype controls.
Western Blot. Lysis, protein quantitation and western blotting of cells and EVs were performed as previously 
described47, with some modifications. Briefly, cells were lysed in a 1% NP-40 lysis buffer with cOmplete Protease 
Inhibitors (Roche, Sigma Aldrich) and sonicated 2 × 10 s on ice. Protein concentrations were determined using 
a micro BCA assay (Thermo Scientific) according to the manufacturer’s instructions. Cell and EV lysates were 
prepared in a reducing or non-reducing (without 2-mercaptoethanol) sample buffer (50 mM Tris-HCl pH 6.8, 5% 
glycerol, 2% SDS, 1.5% 2-mercaptoethanol with bromophenol blue) and heated at 70 °C, 5 min. Lysates (10 µg) 
were electrophoresed and transferred to nitrocellulose, followed by incubation in Ponceau-S.
Non-reduced blots were probed with primary antibodies CD9 (4 µg/mL), CD151 (2 µg/mL) and CD82 
(1:2000), with cell blots being further probed for GAPDH (1:1000) for quantitation of tetraspanin expression, and 
EV blots being further probed for CD63 (1:1000) expression. Reduced blots were probed with ACTB (1:10000), 
TGFBI (1:1000), FLNA (1:1000), HSPA5 (1:1000) and SPOCK2 (1:500). After secondary incubation, blots were 
developed using an ECL detection reagent. Blots were scanned using an Image Quant LAS-4000 Smart Lightbox 
or an Amersham Imager 600 (GE Healthcare Australia, Parramatta, NSW, Australia). Bands were quantitated 
using ImageJ v1.47 software (http://imagej.nih.gov).
Peptide Preparation and iTRAQ Labelling. Isolated RWPE1, CD9 low, CD151 high and WPE1-NB26 
EVs pooled from three separate replicate EV preparations, equivalent to 150 µg, were suspended in ice-cold 0.1 M 
Na2CO3, pH 11, with cOmplete Protease and PhosSTOP phosphatase inhibitors (Roche), sonicated and incubated 
at −20 °C overnight. Samples were concentrated using a 10 kDa centrifugal filter unit (Merck Millipore) and 
washed with 50 mM triethylammonium bicarbonate (TEAB). Samples were dissolved in urea mix (6 M urea, 2 M 
thiourea) and reduced with 20 mM dithiothreitol (DTT) for 45 min at 37 °C followed by alkylation with 40 mM 
iodoacetamide for 1 h at room temperature. Proteins were first digested with 0.04 AU of Lysyl Endopeptidase 
C (Wako, Japan) for 3 h at room temperature followed by digestion with 5 µg of trypsin (after dilution of the 
urea mix to below 1 M urea), 0.3 M thiourea with TEAB, and incubated at 37 °C overnight48. Peptides were spun 
through the 10 kDa filter unit and acidified with formic acid to precipitate lipids. Lipids were removed by cen-
trifugation at 20,000 × g for 20 min. Peptides were desalted using in-house made reverse phase microcolumns as 
previously described49. Briefly, microcolumns consisted of a modified gel loading pipette tip with a C18 Empore 
Disk plug (Sigma Aldrich) packed with a 1 cm layer of Poros Oligo R3 reverse phase resin (Applied Biosystems; 
Thermo Fisher Scientific) dissolved in 70% acetonitrile. Columns were equilibrated using 0.1% trifluoracetic acid 
(TFA) and samples slowly passed through the resin. Columns were washed with 0.1% TFA and bound peptides 
eluted using 50% acetonitrile/0.1% TFA followed by 70% acetonitrile/0.1% TFA.
Purified EV peptide samples were quantitated using a Qubit 2.0 Fluorometer (Thermo Fisher Scientific) and 
50 µg of peptide from each sample used for iTRAQTM labelling. iTRAQTM 4-plex labels (Applied Biosystems) were 
added to lyophilised peptide samples as per the manufacturer’s instructions. Labelled peptides were quantitated 
and mixed in a 1:1:1:1 ratio determined using a micrOTOF-Q II (Bruker Biosciences, Preston, VIC, Australia) 
coupled to a Dionex Ultimate 3000RSLC nanoflow HPLC system (Thermo Fisher Scientific).
Tandem Mass Spectrometry. iTRAQ™ labelled peptides from extracellular vesicles were separated 
offline using hydrophobic interactions chromatography (HILIC)50. Peptides were dried after HILIC separation 
and resuspended in 5 µL of 0.1% TFA. Peptides were loaded on an Acclaim PepMap100 C18 Nano-trap column 
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(2 cm × 100 µm, 5 µm, 100 Å) using 0.1% TFA and separated on an in-house packed Reprosil-Pur C18-AQ 
(3 µm; Dr. Maisch GmbH) analytical column (20 cm × 75 µm) using a Dionex Ultimate® 3000 Nano LC system 
(Thermo Scientific) and eluted at a flow of 250 nL/min. Peptides were analysed an Orbitrap Fusion (Thermo 
Fisher Scientific). Survey scans of peptide precursors from 350 to 1400 m/z were performed at 120,000 resolution 
(at 200 m/z) with a 5 × 105 ion count target, the max injection time was 60 ms. HCD fragmentation with a nor-
malized collision energy of 38, and MS2 analysis in the Orbitrap. The MS2 resolution was set to 30,000 and the 
max injection time was 100 ms. Only those precursors with charge state +2, +3, and +4 were sampled for MS251.
Bioinformatic Analysis. Raw LC-MS/MS data files were analysed using Proteome Discoverer (Version 
1.4.1.14, Thermo Fisher Scientific), employing database searches using both an in-house Mascot server (Version 
2.2.04, Matrix Science, London, UK), and the embedded Sequest HT server with the following criteria: database, 
SwissProt Homo Sapiens protein database (updated 15-01-2015, 20193 sequences), with common contaminants; 
enzyme, trypsin; maximum mussed cleavages, 2; variable modifications included oxidation of Met (M), iTRAQ 
4plex, acetyl (protein N terminus) and Lys (K), deamidation for Asn (N) and Gln (Q), and carbamidomethylation 
of Cys (C) residues as a static modification. The MS and MS/MS results were searched with a precursor mass 
tolerance of 10 ppm, and an MS/MS mass tolerance of 0.05 Da. The Mascot results were filtered in Proteome 
Discoverer using Percolator to ensure the false discovery rate was less than 0.01. Peptides with different amino 
acid sequences or modifications were considered unique. Data were further analysed using FunRich v2.1.252, an 
open access functional enrichment and interaction network tool, to further identify key biological processes and 
pathways in samples.
Zymography. Protease activity of EVs was assessed using 12% casein and 10% gelatin zymogram gels 
(Thermo Fisher) as per the manufacturer’s instructions. Briefly, three individually isolated EV samples for each 
cell line (10 µg) were prepared in a non-reducing sample buffer and run on gels in Tris-Glycine SDS running 
buffer (Thermo Fisher). Proteases were renatured and developed before staining with Colloidal Blue Staining Kit 
(Thermo Fisher). Destaining was performed as per the manufacturer’s instructions.
Proliferation Assay. Cellular proliferation following treatment with EVs was assessed using a Resazurin 
assay as previously described47. Briefly, RWPE1 cells were seeded into a 96-well plate. After an overnight incuba-
tion, 10 µg/mL of RWPE1, CD9 low, Scrambled, CD151 high, Empty Vector and WPE1-NB26 EVs were added to 
wells in growth factor-free K-SFM. A resazurin mix (final concentration 300 µM resazurin, 40 µM methylene blue, 
1 mM potassium hexacyanoferrate (III), 2 mM potassium hexacyanoferrate (II) trihydrate) was added to wells at 
0, 20 and 44 h and incubated for 4 h. Proliferation at 4, 24 and 48 h was assessed using a fluorescence plate reader 
at 544 nm excitation with 590 nm emission wavelengths.
Wound Healing Assay. Wound healing assays were conducted on RWPE1 cells using a modified proto-
col as previously described53. Briefly, RWPE1 cells were grown as confluent monolayers in 12-well plates and 
scratched using a P200 tip. Cellular debris from the wound was removed by washing twice in sterile PBS. Growth 
factor-free K-SFM, containing 10 µg/mL of EVs (as determined by BCA assay), was added to wells. Wounds 
were photographed hourly for 24 h using a Zeiss Axiovert 200 M microscope with a Zeiss Incubator XL-3 489 
attachment (Carl Zeiss, North Ryde, NSW, Australia) maintaining cells at 37 °C/5% CO2. Cellular migration was 
measured using AxioVision v4.9.1 software (Carl Zeiss) by measuring the size of the wound at each time point. 
Three individual measurements were made on each wound and averaged. Three independent experiments with 
a minimum of three replicates per experiment were pooled. Wound closure was calculated as percentage wound 
closure from t = 0.
Invasion Assay. Cellular invasion was assessed using a 96-well Cultrex Invasion Assay kit (Trevigen; 
Bio-Scientific, Gymea, NSW, Australia). A 250 µg/mL solution of Cultrex Reduced Growth Factor Basement 
Membrane Extract (Trevigen) was prepared and 50 µL added to the inserts of a Boyden chamber and incubated 
at 37 °C overnight. Membranes were either pretreated with EVs for 24 h before seeding cells or had EVs added at 
the time of cell seeding. For pretreated wells, 50 µL of EVs (10 µg/mL in growth factor-free K-SFM) were added to 
membranes and incubated at 37 °C for 24 h. RWPE1 cells were added to the top chambers at 5 × 104 cells per well 
on top of the EV solution for pretreated wells or added with EVs for co-addition wells (100 µL total volume per 
invasion chamber well). Complete K-SFM was added to bottom chambers. Plates were incubated for 48 h to assess 
invasion. Wells were washed, and invasive cells dissociated from the membranes and stained with Calcein-AM 
using the supplied reagents as per the manufacturer’s instructions. Calcein-AM fluorescence was detected using 
a fluorescence plate reader at 485 nm excitation with 520 nm wavelengths.
Statistical analysis. One-way ANOVA, with Bonferroni’s multiple comparisons test, was used for analy-
sis of western blot flow cytometry and NTA data. Wound healing assay and invasion assay data were analysed 
using a Kruskal-Wallis test with Dunn’s multiple comparisons. Two-way ANOVA with Bonferroni’s multiple 
comparisons was used for analysis of proliferation data. Differences were considered statistically significant for 
P-values < 0.05. All analyses were performed using GraphPad Prism v6.0.4 software (GraphPad, San Diego, CA, 
USA). Data are presented as the mean ± standard error of the mean (SEM).
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